Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Guanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | NT5E | P21589 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 3/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiourea SCHEMBL1577311 | 0.92 | CYP2D6 (0.58) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| Urea SCHEMBL11794762 | 0.89 | ALDH1A1 (0.57) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| Hno SCHEMBL3391939 | 0.89 | GAA (0.56) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| Hydroxyamine SCHEMBL599912 | 0.89 | ALDH1A1 (0.58) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| Hydrazine SCHEMBL8861759 | 0.89 | ALDH1A1 (0.58) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| Methylamine SCHEMBL4135110 | 0.89 | ALDH1A1 (0.58) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| SCHEMBL6960519 | 0.89 | GAA (0.56) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| SCHEMBL11432043 | 0.89 | GAA (0.62) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| SCHEMBL34 | 0.89 | GAA (0.62) | CYP2D6MAPK1ALDH1A1CA1CA2 | |
| SCHEMBL31313 | 0.89 | GAA (0.62) | CYP2D6MAPK1ALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250286141-A1 | ELECTROLYTE SYSTEMS INCLUDING PERFORMANCE-ENHANCING ADDITIVES, AND ELECTROCHEMICAL CELLS INCLUDING THE SAME | Lyten, Inc. | 2025-09-11 | — | — | US | claimed |
| WO-2025036900-A1 | HAIR DYEING COMPOSITION | KAO CORPORATION (JP) | 2025-02-20 | — | — | WO | claimed |
| EP-2338923-B1 | Polyurethane with a biocidal polyuric material as comonomer | OBERWALDER SEBASTIAN (DE) | 2017-10-18 | — | — | EP | claimed |
| US-9738647-B2 | Methods for the synthesis of polycyclic guanidine compounds | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2017-08-22 | — | — | US | claimed |
| EP-2515648-B1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER INC (US) | 2017-08-16 | — | — | EP | claimed |
| US-20140194622-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2014-07-10 | — | — | US | claimed |
| US-8642771-B2 | Methods for the synthesis of polycyclic guanidine compounds | NOVOMER, INC. (US) | 2014-02-04 | — | — | US | claimed |
| EP-2515648-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | Novomer, Inc. (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120259112-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2012-10-11 | — | — | US | claimed |
| CN-102665406-A | Method for synthesizing polycyclic guanidine compounds | NOVOMER INC | 2012-09-12 | — | — | CN | claimed |
| WO-2011079041-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER, INC. (US) | 2011-06-30 | — | — | WO | claimed |
| WO-2025045680-A1 | METHOD TO MAKE BICYCLIC GUANIDINES | EVONIK OPERATIONS GMBH (DE) | 2025-03-06 | — | — | WO | disclosed |
| WO-2025036900-A1 | HAIR DYEING COMPOSITION | KAO CORPORATION (JP) | 2025-02-20 | — | — | WO | disclosed |
| US-9738647-B2 | Methods for the synthesis of polycyclic guanidine compounds | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2017-08-22 | — | — | US | disclosed |
| EP-2515648-B1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | NOVOMER INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION | 2002-10-24 | — | — | US | disclosed |
| US-6417185-B1 | HETEROCYCLIC ENZYME INHIBITORS | CHIRON CORPORATION | 2002-07-09 | — | — | US | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194622-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | GNMT, GMPS, GDA | CYP2D6 2208/4885MAPK1 3986/4885ALDH1A1 2770/4885 |
| US-20120259112-A1 | METHODS FOR THE SYNTHESIS OF POLYCYCLIC GUANIDINE COMPOUNDS | GNMT, GMPS, GDA | CYP2D6 2208/4885MAPK1 3986/4885ALDH1A1 2770/4885 |
| US-20020156087-A1 | Inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | CYP2D6 2653/4885MAPK1 436/4885ALDH1A1 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.